12/3
08:00 am
pcrx
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/2
08:36 pm
pcrx
Does Pacira's ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? [Yahoo! Finance]
Low
Report
Does Pacira's ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? [Yahoo! Finance]
12/2
08:00 am
pcrx
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
Low
Report
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
11/26
05:38 pm
pcrx
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical [Yahoo! Finance]
Low
Report
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical [Yahoo! Finance]
11/26
04:01 pm
pcrx
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
Low
Report
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
11/18
01:18 pm
pcrx
Pacira BioSciences (NASDAQ:PCRX) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Pacira BioSciences (NASDAQ:PCRX) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/17
08:06 am
pcrx
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Low
Report
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
11/11
09:51 am
pcrx
Pacira BioSciences gains as investor calls for full sales process [Seeking Alpha]
Low
Report
Pacira BioSciences gains as investor calls for full sales process [Seeking Alpha]
11/11
08:00 am
pcrx
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Medium
Report
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
11/10
08:18 pm
pcrx
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business [Yahoo! Finance]
Medium
Report
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business [Yahoo! Finance]
11/10
08:09 pm
pcrx
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
Medium
Report
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
11/8
01:17 pm
pcrx
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at
Wall Street
Medium
Report
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at
Wall Street
11/8
07:58 am
pcrx
Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Mixed Financials Driving The Negative Sentiment? [Yahoo! Finance]
Medium
Report
Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Mixed Financials Driving The Negative Sentiment? [Yahoo! Finance]
11/7
12:17 pm
pcrx
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
11/6
04:28 pm
pcrx
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance [Yahoo! Finance]
Medium
Report
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance [Yahoo! Finance]
11/6
04:01 pm
pcrx
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
Medium
Report
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
11/5
08:00 am
pcrx
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
Low
Report
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
11/4
07:00 am
pcrx
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
Medium
Report
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
10/30
08:00 am
pcrx
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
Low
Report
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
10/28
08:00 am
pcrx
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
Low
Report
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
10/27
08:00 am
pcrx
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
Low
Report
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
10/23
08:00 am
pcrx
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
Low
Report
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
10/21
08:30 am
pcrx
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
Low
Report
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
10/20
04:01 pm
pcrx
Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
Medium
Report
Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
10/3
08:00 am
pcrx
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)